{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:12:19Z","timestamp":1778933539856,"version":"3.51.4"},"reference-count":242,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022762","name":"Universit\u00e4t Witten\/Herdecke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EH 192\/5-3"],"award-info":[{"award-number":["EH 192\/5-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["IFF 2024-91"],"award-info":[{"award-number":["IFF 2024-91"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024068","name":"Witten\/Herdecke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Engineering Microbiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.engmic.2024.100140","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T12:15:54Z","timestamp":1707394554000},"page":"100140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of homologous recombination\/recombineering on human adenovirus genome engineering: Not the only but the most competent solution"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8321-7814","authenticated-orcid":false,"given":"Lisa-Marie","family":"Dawson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montaha","family":"Alshawabkeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2242-2450","authenticated-orcid":false,"given":"Katrin","family":"Schr\u00f6er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Arakrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6243-6286","authenticated-orcid":false,"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0001","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"ROWE","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0002","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/TP.0000000000003988","article-title":"Adenovirus infection and transplantation","volume":"106","author":"Al-Heeti","year":"2022","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s15010-020-01484-7","article-title":"Adenovirus diseases: a systematic review and meta-analysis of 228 case reports","volume":"49","author":"Gu","year":"2021","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0004","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"issue":"6447","key":"10.1016\/j.engmic.2024.100140_bib0005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/365597a0","article-title":"Nobel goes to discoverers of 'split genes'","volume":"365","author":"Carr","year":"1993","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0006","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0007","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0008","article-title":"Adenoviral vector-based vaccine platform for COVID-19: current status","volume":"11","author":"Chavda","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.engmic.2024.100140_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-012621-102252","article-title":"COVID-19 vaccines: adenoviral vectors","volume":"73","author":"Jacob-Dolan","year":"2022","journal-title":"Annu. Rev. Med."},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0010","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/82449","article-title":"DNA cloning by homologous recombination in Escherichia coli","volume":"18","author":"Zhang","year":"2000","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0011","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11262-017-1487-2","article-title":"Getting genetic access to natural adenovirus genomes to explore vector diversity","volume":"53","author":"Zhang","year":"2017","journal-title":"Virus Genes"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0012","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nbt.2183","article-title":"Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting","volume":"30","author":"Fu","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0013","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.celrep.2017.05.008","article-title":"An engineered virus library as a resource for the spectrum-wide exploration of virus and vector diversity","volume":"19","author":"Zhang","year":"2017","journal-title":"Cell Rep"},{"issue":"17","key":"10.1016\/j.engmic.2024.100140_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176370","article-title":"High-throughput cloning and characterization of emerging adenovirus types 70, 73, 74, and 75","volume":"21","author":"Zhang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O'Hara","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"6869","key":"10.1016\/j.engmic.2024.100140_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0017","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors, molecular therapy","volume":"10","author":"Tatsis","year":"2004","journal-title":"J. American Soci. Gene Ther."},{"issue":"1\u20133","key":"10.1016\/j.engmic.2024.100140_bib0018","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0378-1119(86)90321-5","article-title":"Human adenovirus cloning vectors based on infectious bacterial plasmids","volume":"50","author":"Ghosh-Choudhury","year":"1986","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030334","article-title":"Recent advances in the development of adenovirus-vectored vaccines for parasitic infections","volume":"16","author":"Koger-Pease","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0020","first-page":"668","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens, Molecular therapy : the journal of the American Society of","volume":"22","author":"Antrobus","year":"2014","journal-title":"Gene Ther."},{"issue":"9666","key":"10.1016\/j.engmic.2024.100140_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(09)60470-0","article-title":"HIV-1 step study","volume":"373","author":"Dalgleish","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0022","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COH.0b013e32833cfe4c","article-title":"Novel adenovirus vector-based vaccines for HIV-1","volume":"5","author":"Barouch","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0023","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/655468","article-title":"AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein","volume":"202","author":"Schooley","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.engmic.2024.100140_bib0024","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0076-6879(02)46075-2","article-title":"Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes","volume":"346","author":"Rubinchik","year":"2002","journal-title":"Meth. Enzymol."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0025","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/JVI.80.6.2738-2746.2006","article-title":"Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus","volume":"80","author":"Wang","year":"2006","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0026","doi-asserted-by":"crossref","first-page":"e5308","DOI":"10.1371\/journal.pone.0005308","article-title":"Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine","volume":"4","author":"Richardson","year":"2009","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0027","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1128\/CVI.00467-09","article-title":"Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector","volume":"17","author":"Pratt","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0028","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1021\/mp500646d","article-title":"A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection","volume":"12","author":"Choi","year":"2015","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0029","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1038\/s41598-020-60238-5","article-title":"Characterization of a Species E Adenovirus Vector as a Zika virus vaccine","volume":"10","author":"Bullard","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0030","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ymthe.2022.01.034","article-title":"Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens","volume":"30","author":"Coughlan","year":"2022","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009308","article-title":"Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses","volume":"15","author":"Powers","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239780","article-title":"Cocaine vaccine dAd5GNE protects against moderate daily and high-dose \"binge\" cocaine use","volume":"15","author":"Havlicek","year":"2020","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0033","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/mt.2010.280","article-title":"Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs","volume":"19","author":"Hicks","year":"2011","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0034","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2174\/187152711799219334","article-title":"Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus","volume":"10","author":"Koob","year":"2011","journal-title":"CNS Neurol Disord Drug Targ."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0035","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/npp.2011.200","article-title":"Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects","volume":"37","author":"Wee","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0036","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/npp.2013.114","article-title":"Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter","volume":"38","author":"Maoz","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/humc.2013.231","article-title":"Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine","volume":"25","author":"Hicks","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.engmic.2024.100140_bib0038","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-018-0072-6","article-title":"Incorporation of NS1 and prM\/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein","volume":"3","author":"Liu","year":"2018","journal-title":"NPJ vaccines"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0039","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41426-018-0102-5","article-title":"An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques","volume":"7","author":"Feng","year":"2018","journal-title":"Emerg. Microbes. Infect."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/oxfordjournals.aje.a121378","article-title":"An analysis of hospitalizations for acute respiratory disease in recruits immunized with adenovirus type 4 and type 7 vaccines","volume":"95","author":"Dudding","year":"1972","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0041","doi-asserted-by":"crossref","first-page":"e31177","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin","volume":"7","author":"Alexander","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0042","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.1038\/s41598-023-33529-w","article-title":"Structural characterisation of hemagglutinin from seven Influenza A H1N1 strains reveal diversity in the C05 antibody recognition site","volume":"13","author":"Ghafoori","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01092-17","article-title":"Combination adenovirus and protein vaccines prevent infection or reduce viral burden after heterologous Clade C simian-human immunodeficiency virus mucosal challenge","volume":"92","author":"Malherbe","year":"2018","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0044","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/s41598-018-35755-z","article-title":"Efficacy of a T cell-biased adenovirus vector as a zika virus vaccine","volume":"8","author":"Bullard","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0046","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0047","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1473-3099(22)00594-1","article-title":"Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial","volume":"23","author":"Manno","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0048","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3928\/0191-3913-19890301-14","article-title":"The use of part-time occlusion for early onset unilateral exotropia","volume":"26","author":"Freeman","year":"1989","journal-title":"J Pediatr. Ophthalmol. Strabismus"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0049","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0050","first-page":"e688","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study, The lancet","volume":"7","author":"Baden","year":"2020","journal-title":"HIV"},{"issue":"10143","key":"10.1016\/j.engmic.2024.100140_bib0051","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0052","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202820","article-title":"Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge","volume":"13","author":"Cox","year":"2018","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0054","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.engmic.2024.100140_bib0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-019-0150-4","article-title":"Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations","volume":"4","author":"Salisch","year":"2019","journal-title":"NPJ vaccines"},{"issue":"41","key":"10.1016\/j.engmic.2024.100140_bib0056","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0057","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults","volume":"388","author":"Falsey","year":"2023","journal-title":"New England j. med."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0058","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged \u226560 years","volume":"222","author":"Williams","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0059","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1093\/nar\/gni035","article-title":"Simple and highly efficient BAC recombineering using galK selection","volume":"33","author":"Warming","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008954","article-title":"Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48\/MVA in combination with TLR-7 stimulation","volume":"16","author":"Bricker","year":"2020","journal-title":"PLoS Pathog."},{"issue":"7617","key":"10.1016\/j.engmic.2024.100140_bib0061","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature"},{"issue":"420","key":"10.1016\/j.engmic.2024.100140_bib0062","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4163","article-title":"Durability and correlates of vaccine protection against Zika virus in rhesus monkeys","volume":"9","author":"Abbink","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0063","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","article-title":"Enzymatic assembly of DNA molecules up to several hundred kilobases","volume":"6","author":"Gibson","year":"2009","journal-title":"Nat. Methods"},{"issue":"15","key":"10.1016\/j.engmic.2024.100140_bib0064","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","article-title":"Bronchiolitis-associated hospitalizations among US children, 1980-1996","volume":"282","author":"Shay","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0065","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/infdis\/jiac481","article-title":"Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV-seropositive children 12-23 months of age","volume":"227","author":"D\u00edez-Domingo","year":"2023","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196546","article-title":"Correction: a prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS ONE"},{"issue":"15","key":"10.1016\/j.engmic.2024.100140_bib0067","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0068","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/imm.12226","article-title":"Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection","volume":"141","author":"Elias","year":"2014","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0069","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.engmic.2024.100140_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1058227","article-title":"Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso","volume":"13","author":"Morter","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.engmic.2024.100140_bib0071","article-title":"Functions of exosomal non-coding RNAs to the infection with Mycobacterium tuberculosis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.engmic.2024.100140_bib0072","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.ijid.2022.03.011","article-title":"The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB","volume":"124","author":"Chakaya","year":"2022","journal-title":"Int. J. Infect. Dis."},{"issue":"29","key":"10.1016\/j.engmic.2024.100140_bib0073","doi-asserted-by":"crossref","first-page":"47474","DOI":"10.18632\/oncotarget.17666","article-title":"5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy","volume":"8","author":"Cappuccini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.engmic.2024.100140_bib0074","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3389\/fimmu.2019.02005","article-title":"Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 antigens protects ferrets against influenza virus challenge","volume":"10","author":"McMahon","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0075","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.32470","article-title":"A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice","volume":"76","author":"Donnison","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0076","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat Commun"},{"issue":"7830","key":"10.1016\/j.engmic.2024.100140_bib0077","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0078","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors","volume":"9","author":"L\u00f3pez-Camacho","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0079","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1101\/gr.143000","article-title":"DNA cloning using in vitro site-specific recombination","volume":"10","author":"Hartley","year":"2000","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0080","doi-asserted-by":"crossref","DOI":"10.3390\/v11040322","article-title":"Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against chikungunya virus","volume":"11","author":"L\u00f3pez-Camacho","year":"2019","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0081","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0082","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2144\/000114101","article-title":"Single step BP\/LR combined Gateway reactions","volume":"55","author":"Liang","year":"2013","journal-title":"BioTechniques"},{"issue":"10224","key":"10.1016\/j.engmic.2024.100140_bib0083","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"10255","key":"10.1016\/j.engmic.2024.100140_bib0084","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0085","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11040948","article-title":"B.O.T.W.G.O.A.-C.-V.O.T.A.N.M.C.O.A. On. COVID-19, vaccines, and thrombotic events: a narrative review","volume":"11","author":"Abrignani","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0086","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1080\/21645515.2015.1042193","article-title":"Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine","volume":"11","author":"Zhang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0087","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4161\/hv.27340","article-title":"Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice","volume":"10","author":"Xiao","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0088","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140794","article-title":"A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","volume":"131","author":"Matsuda","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0089","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/jvi.70.7.4805-4810.1996","article-title":"Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli","volume":"70","author":"Chartier","year":"1996","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0090","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.vaccine.2017.01.016","article-title":"Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen","volume":"35","author":"Andersson","year":"2017","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0091","doi-asserted-by":"crossref","DOI":"10.3390\/v14081779","article-title":"Construction and evaluation of recombinant adenovirus candidate vaccines for chikungunya virus","volume":"14","author":"Cao","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.engmic.2024.100140_bib0092","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ebiom.2016.09.028","article-title":"Preventative Vaccines for Zika Virus Outbreak: preliminary Evaluation","volume":"13","author":"Kim","year":"2016","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0093","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278878","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia","volume":"18","author":"Lioznov","year":"2023","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0094","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0095","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0096","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0097","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/M15-0880","article-title":"Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial","volume":"164","author":"Baden","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"Pt 11","key":"10.1016\/j.engmic.2024.100140_bib0098","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/vir.0.83119-0","article-title":"High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector","volume":"88","author":"Vogels","year":"2007","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0099","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174728","article-title":"Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform","volume":"12","author":"Salisch","year":"2017","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201603-0654OC","article-title":"Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial","volume":"195","author":"van Zyl-Smit","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0101","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v8030078","article-title":"A novel vaccine approach for chagas disease using rare adenovirus serotype 48 vectors","volume":"8","author":"Farrow","year":"2016","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0102","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2017.10.079","article-title":"The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes","volume":"36","author":"von Delft","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0103","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jviromet.2009.09.016","article-title":"The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use","volume":"163","author":"Di Lullo","year":"2010","journal-title":"J. Virol. Methods"},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0104","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"New England j. med."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0106","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01722-17","article-title":"Recombinant chimpanzee adenovirus vaccine AdC7-M\/E protects against zika virus infection and testis damage","volume":"92","author":"Xu","year":"2018","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0107","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/nprot.2010.134","article-title":"An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector","volume":"5","author":"Zhou","year":"2010","journal-title":"Nat Protoc"},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0108","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0109","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.engmic.2024.100140_bib0110","article-title":"Impact of a blood-stage vaccine on Plasmodium vivax malaria, medRxiv","author":"Hou","year":"2022","journal-title":"Preprint Server Health Sci."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0111","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jir842","article-title":"Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis","volume":"205","author":"Maroof","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0113","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan","volume":"29","author":"Younis","year":"2021","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0114","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/cid\/ciz653","article-title":"First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion","volume":"70","author":"Cicconi","year":"2020","journal-title":"Official Publicat. Infectious Dis. Soc. America"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0115","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2007.135","article-title":"A protocol for rapid generation of recombinant adenoviruses using the AdEasy system","volume":"2","author":"Luo","year":"2007","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency","volume":"13","author":"Raper","year":"2002","journal-title":"Hum. Gene Ther."},{"issue":"24","key":"10.1016\/j.engmic.2024.100140_bib0117","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","article-title":"A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal","volume":"93","author":"Parks","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0118","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nprot.2009.4","article-title":"A rapid protocol for construction and production of high-capacity adenoviral vectors","volume":"4","author":"Jager","year":"2009","journal-title":"Nat Protoc"},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0119","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/JVI.76.9.4181-4189.2002","article-title":"Cre levels limit packaging signal excision efficiency in the Cre\/loxP helper-dependent adenoviral vector system","volume":"76","author":"Ng","year":"2002","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/89349","article-title":"Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination","volume":"19","author":"Uma\u00f1a","year":"2001","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0121","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/1074-7613(94)90074-4","article-title":"MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses","volume":"1","author":"Yang","year":"1994","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0122","first-page":"1","article-title":"No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0123","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-0934(97)00129-8","article-title":"Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations","volume":"68","author":"Alemany","year":"1997","journal-title":"J. Virol. Methods"},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0124","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/btpr.25","article-title":"Towards purification of adenoviral vectors based on membrane technology","volume":"24","author":"Peixoto","year":"2008","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.engmic.2024.100140_bib0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-4939-7231-9_28","article-title":"Production, Purification, and Titration of First-Generation Adenovirus Vectors","volume":"1654","author":"Kratzer","year":"2017","journal-title":"Methods Mol. Biol."},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0126","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/jvi.70.11.7498-7509.1996","article-title":"Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy","volume":"70","author":"Mittereder","year":"1996","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0127","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/viro.2002.1406","article-title":"Evaluation of accuracy and precision of adenovirus absorptivity at 260nm under conditions of complete DNA disruption","volume":"295","author":"Sweeney","year":"2002","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/hum.2006.17.531","article-title":"Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction","volume":"17","author":"Puntel","year":"2006","journal-title":"Hum. Gene Ther."},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0129","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3390\/v6072899","article-title":"Coat as a dagger: the use of capsid proteins to perforate membranes during non-enveloped DNA viruses trafficking","volume":"6","author":"Bilkova","year":"2014","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hum.2009.155","article-title":"MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus","volume":"21","author":"Suzuki","year":"2010","journal-title":"Hum. Gene Ther."},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0131","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/JVI.02385-06","article-title":"Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response","volume":"81","author":"Ullman","year":"2007","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.engmic.2024.100140_bib0132","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.1128\/JVI.77.13.7689-7695.2003","article-title":"Episomal persistence o (2) (f recombinant adenoviral vector genomes during the cell cycle in vivo","volume":"77","author":"Ehrhardt","year":"2003","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0133","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/v5061500","article-title":"The role of chromatin in adenoviral vector function","volume":"5","author":"Wong","year":"2013","journal-title":"Viruses"},{"issue":"17","key":"10.1016\/j.engmic.2024.100140_bib0134","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1128\/JVI.00796-09","article-title":"Host cell detection of noncoding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of tran (2) (sgene expression","volume":"83","author":"Ross","year":"2009","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0135","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2013.071","article-title":"Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors","volume":"24","author":"Brunetti-Pierri","year":"2013","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0136","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V95.3.820.003k32_820_828","article-title":"Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector","volume":"95","author":"Balagu\u00e9","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0137","first-page":"562","article-title":"Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A","volume":"82","author":"Zhang","year":"1999","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0138","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.93.12.5731","article-title":"A new adenoviral vector: replacement of all viral coding sequences with 28kb of DNA independently expressing both full-length dystrophin and beta-galactosidase","volume":"93","author":"Kochanek","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0139","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood.V99.11.3923","article-title":"A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo","volume":"99","author":"Ehrhardt","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0140","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/blood-2003-01-0314","article-title":"A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia","volume":"102","author":"Ehrhardt","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0141","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/hum.2005.16.811","article-title":"Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector","volume":"16","author":"Brunetti-Pierri","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"22","key":"10.1016\/j.engmic.2024.100140_bib0142","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1073\/pnas.96.22.12816","article-title":"Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons","volume":"96","author":"Morral","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0143","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/mt.2008.257","article-title":"Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates, Molecular therapy","volume":"17","author":"Brunetti-Pierri","year":"2009","journal-title":"J. American Soci. Gene Ther."},{"issue":"23","key":"10.1016\/j.engmic.2024.100140_bib0144","doi-asserted-by":"crossref","first-page":"13282","DOI":"10.1073\/pnas.241506298","article-title":"Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector","volume":"98","author":"Kim","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/sj.gt.3302819","article-title":"Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector","volume":"14","author":"Oka","year":"2007","journal-title":"Gene Ther."},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0146","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/gt.2013.38","article-title":"PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice","volume":"20","author":"Leggiero","year":"2013","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0147","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/ATVBAHA.117.309565","article-title":"Apo A-I (Apolipoprotein A-I) vascular gene therapy provides durable protection against atherosclerosis in hyperlipidemic rabbits","volume":"38","author":"Wacker","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0148","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.gene.2003.11.024","article-title":"Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice","volume":"327","author":"Pastore","year":"2004","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0149","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/hum.2018.120","article-title":"ABCA1 overexpression in endothelial cells in vitro enhances ApoAI-mediated cholesterol efflux and decreases inflammation","volume":"30","author":"Stamatikos","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"7563","key":"10.1016\/j.engmic.2024.100140_bib0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature14600","article-title":"Viral-genetic tracing of the input-output organization of a central noradrenaline circuit","volume":"524","author":"Schwarz","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0151","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1096\/fj.01-0321fje","article-title":"Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo","volume":"15","author":"Soudais","year":"2001","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0152","first-page":"105","article-title":"Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system, Molecular therapy : the journal of the American Society of","volume":"2","author":"Zou","year":"2000","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0153","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0006-8993(94)91919-4","article-title":"Adenoviral vectors as functional retrograde neuronal tracers","volume":"648","author":"Ridoux","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.engmic.2024.100140_bib0154","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neurobiolaging.2018.02.008","article-title":"Age-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatum","volume":"66","author":"Kritzinger","year":"2018","journal-title":"Neurobiol. Aging"},{"issue":"14","key":"10.1016\/j.engmic.2024.100140_bib0155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98202","article-title":"Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate","volume":"3","author":"Mestre-Franc\u00e9s","year":"2018","journal-title":"JCI insight"},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0156","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/jgm.2641","article-title":"Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration","volume":"14","author":"Dong","year":"2012","journal-title":"J Gene Med"},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0157","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1128\/jvi.65.8.4114-4123.1991","article-title":"The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor","volume":"65","author":"Gooding","year":"1991","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0158","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/mt.2011.58","article-title":"Rescue from respiratory dysfunction by transduction of full-length dystrophin to diaphragm via the peritoneal cavity in utrophin\/dystrophin double knockout mice","volume":"19","author":"Ishizaki","year":"2011","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0159","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/hum.2012.003","article-title":"Capsid-modified adenoviral vectors for improved muscle-directed gene therapy","volume":"23","author":"Guse","year":"2012","journal-title":"Hum. Gene Ther."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103643","article-title":"High-capacity adenoviral vectors: expanding the scope of gene therapy","volume":"21","author":"Ricobaraza","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.engmic.2024.100140_bib0161","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood-2016-04-711580","article-title":"In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors","volume":"128","author":"Richter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.engmic.2024.100140_bib0162","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.omtm.2023.03.008","article-title":"HDAd6\/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells, Molecular therapy","volume":"29","author":"Wang","year":"2023","journal-title":"Methods clinical develop."},{"issue":"15","key":"10.1016\/j.engmic.2024.100140_bib0163","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/bloodadvances.2022007975","article-title":"In vivo HSC transduction in rhesus macaques with an HDAd5\/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4","volume":"6","author":"Wang","year":"2022","journal-title":"Blood adv."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0164","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0298-180","article-title":"Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity","volume":"18","author":"Schiedner","year":"1998","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF03402113","article-title":"Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector","volume":"6","author":"O'Neal","year":"2000","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0166","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2003-05-1426","article-title":"Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A","volume":"103","author":"Brown","year":"2004","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.engmic.2024.100140_bib0167","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0168","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/hum.2006.17.391","article-title":"Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates","volume":"17","author":"Brunetti-Pierri","year":"2006","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0169","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymthe.2005.08.006","article-title":"Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice, Molecular therapy","volume":"13","author":"Kiang","year":"2006","journal-title":"J. American Soc. Gene Ther."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/mt.2008.23","article-title":"Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin\/dystrophin double knockout mice, Molecular therapy","volume":"16","author":"Kawano","year":"2008","journal-title":"J. American Soc. Gene Ther."},{"issue":"21","key":"10.1016\/j.engmic.2024.100140_bib0171","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/01.CIR.0000066913.69844.B2","article-title":"Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia","volume":"107","author":"Belalcazar","year":"2003","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.engmic.2024.100140_bib0172","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1093\/hmg\/ddt148","article-title":"Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice","volume":"22","author":"Unzu","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0173","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/hum.2013.152","article-title":"Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type VII mice","volume":"25","author":"Ariza","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0174","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/gt.2015.107","article-title":"Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1","volume":"23","author":"Castello","year":"2016","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0175","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/hum.2017.201","article-title":"Transducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy","volume":"29","author":"Cao","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"5 Pt 1","key":"10.1016\/j.engmic.2024.100140_bib0176","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1525-0016(03)00059-5","article-title":"Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter","volume":"7","author":"Toietta","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.engmic.2024.100140_bib0177","first-page":"371","article-title":"Preparation of helper-dependent adenoviral vectors","volume":"69","author":"Ng","year":"2002","journal-title":"Methods Mol. Med."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0178","first-page":"846","article-title":"Improved system for helper-dependent adenoviral vector production, Molecular therapy : the journal of the American Society of","volume":"8","author":"Palmer","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.engmic.2024.100140_bib0179","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.omtm.2023.03.008","article-title":"HDAd6\/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells, Molecular therapy","volume":"29","author":"Wang","year":"2023","journal-title":"Methods & clinical develop."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0180","doi-asserted-by":"crossref","DOI":"10.3390\/v15020358","article-title":"A renaissance for oncolytic adenoviruses?","volume":"15","author":"Blanchette","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.engmic.2024.100140_bib0181","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0182","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061504","article-title":"Oncolytic adenoviruses: strategies for improved targeting and specificity","volume":"12","author":"Hajeri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.engmic.2024.100140_bib0183","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194701","article-title":"Oncolytic adenoviruses: the cold war against cancer finally turns hot","volume":"14","author":"Oronsky","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0184","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0185","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1128\/jvi.70.10.6839-6846.1996","article-title":"Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism","volume":"70","author":"Krasnykh","year":"1996","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0186","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2011.03.021","article-title":"Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma","volume":"307","author":"Chen","year":"2011","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0187","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00535-012-0711-z","article-title":"Chimeric 5\/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44\u207a gastric cancer cells via attenuating Wnt signaling","volume":"48","author":"Wang","year":"2013","journal-title":"J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0188","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092694","article-title":"Targeting CD46 enhances anti-tumoral activity of adenovirus Type 5 for bladder cancer","volume":"19","author":"Do","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0189","first-page":"164","article-title":"Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells, Molecular therapy : the journal of the American Society of","volume":"14","author":"Bauerschmitz","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.engmic.2024.100140_bib0190","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.omtm.2020.06.010","article-title":"Transient chimeric Ad5\/37 fiber enhances NK-92 carrier cell-mediated delivery of oncolytic adenovirus type 5 to tumor cells, molecular therapy","volume":"18","author":"Gao","year":"2020","journal-title":"Methods clinical develop."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0191","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"Kuhn","year":"2008","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0192","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.engmic.2024.100140_bib0193","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.omto.2016.12.001","article-title":"OvAd1, a Novel, potent, and selective chimeric oncolytic virus developed for ovarian cancer by 3D-directed evolution","volume":"4","author":"Kuhn","year":"2017","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0194","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/cgt.2010.79","article-title":"Oncolytic adenovirus based on serotype 3","volume":"18","author":"Hemminki","year":"2011","journal-title":"Cancer Gene Ther."},{"issue":"8","key":"10.1016\/j.engmic.2024.100140_bib0195","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4161\/cbt.8.8.7913","article-title":"A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers","volume":"8","author":"Chang","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.engmic.2024.100140_bib0196","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0197","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265717","article-title":"Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy","volume":"6","author":"Zafar","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0198","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/1535-7163.MCT-07-2429","article-title":"A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers","volume":"7","author":"Wang","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0199","doi-asserted-by":"crossref","DOI":"10.3390\/v15010182","article-title":"Development of oncolytic vectors based on human adenovirus Type 6 for cancer treatment","volume":"15","author":"Osipov","year":"2023","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0200","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0201","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.engmic.2024.100140_bib0202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1535-6108(02)00060-0","article-title":"Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents","volume":"1","author":"Johnson","year":"2002","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0203","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1089\/10430349950017725","article-title":"A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma","volume":"10","author":"Hallenbeck","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0304-3835(02)00017-4","article-title":"Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells","volume":"180","author":"Kim","year":"2002","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.engmic.2024.100140_bib0205","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.engmic.2024.100140_bib0206","first-page":"4200","article-title":"The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts","volume":"59","author":"Yu","year":"1999","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.engmic.2024.100140_bib0207","first-page":"1498","article-title":"Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy","volume":"59","author":"Yu","year":"1999","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0208","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1172\/JCI9180","article-title":"Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen","volume":"106","author":"Kurihara","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0209","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.molonc.2011.10.001","article-title":"Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer","volume":"5","author":"Liu","year":"2011","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0211","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2013.229","article-title":"ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models","volume":"25","author":"Dong","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0212","first-page":"541","article-title":"Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers, Clinical cancer research : an official journal of the American Association for","volume":"16","author":"Oberg","year":"2010","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0213","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0214","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.engmic.2024.100140_bib0215","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","article-title":"Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein","volume":"74","author":"Doronin","year":"2000","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0216","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0042-6822(87)90441-7","article-title":"Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection","volume":"156","author":"Barker","year":"1987","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0217","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1128\/jvi.52.2.336-343.1984","article-title":"Adenovirus cyt+ locus, which controls cell transformation and tumorigenicity, is an allele of lp+ locus, which codes for a 19-kilodalton tumor antigen","volume":"52","author":"Subramanian","year":"1984","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0218","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0092-8674(79)90275-7","article-title":"Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells","volume":"17","author":"Jones","year":"1979","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0219","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nbt887","article-title":"E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models","volume":"21","author":"Wang","year":"2003","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/07357908909038287","article-title":"Cellular resistance to drugs","volume":"7","author":"Krishan","year":"1989","journal-title":"Cancer Invest."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0221","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/cgt.2008.46","article-title":"An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors","volume":"16","author":"Lei","year":"2009","journal-title":"Cancer Gene Ther."},{"issue":"3\u20134","key":"10.1016\/j.engmic.2024.100140_bib0222","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/hum.2020.222","article-title":"Oncolytic adenovirus type 3 coding for cd40l facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples","volume":"32","author":"Zafar","year":"2021","journal-title":"Hum. Gene Ther."},{"issue":"10","key":"10.1016\/j.engmic.2024.100140_bib0223","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1490856","article-title":"CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy","volume":"7","author":"Zafar","year":"2018","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.engmic.2024.100140_bib0224","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1101-1035","article-title":"Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy","volume":"19","author":"Ramachandra","year":"2001","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.engmic.2024.100140_bib0225","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41417-020-00226-z","article-title":"Ad5\/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes","volume":"28","author":"Zafar","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0226","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020198","article-title":"Rodents versus pig model for assessing the performance of serotype chimeric Ad5\/3 oncolytic adenoviruses","volume":"11","author":"Koodie","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0227","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0228","first-page":"31","article-title":"Tumor-selective replication, cytotoxicity and GM-CSF production of oncolytic recombinant adenovirus in KH901 injection","volume":"38","author":"Shen","year":"2007","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0229","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21873\/anticanres.16190","article-title":"Treatment of human pancreatic cancers following local and systemic administration of oncolytic adenovirus serotype 35","volume":"43","author":"Ono","year":"2023","journal-title":"Anticancer Res."},{"issue":"16_suppl","key":"10.1016\/j.engmic.2024.100140_bib0230","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","article-title":"CORE1: phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)","volume":"40","author":"Li","year":"2022","journal-title":"J. Clinical Oncology"},{"issue":"20","key":"10.1016\/j.engmic.2024.100140_bib0231","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0232","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG (1) (7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.engmic.2024.100140_bib0233","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301377","article-title":"Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?","volume":"8","author":"Kirn","year":"2001","journal-title":"Gene Ther."},{"issue":"22","key":"10.1016\/j.engmic.2024.100140_bib0234","first-page":"6359","article-title":"Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.engmic.2024.100140_bib0235","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"Ganly","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.engmic.2024.100140_bib0236","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/3902","article-title":"ONYX-015: clinical data are encouraging","volume":"4","author":"Kirn","year":"1998","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0237","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat. Med."},{"issue":"5286","key":"10.1016\/j.engmic.2024.100140_bib0238","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.engmic.2024.100140_bib0239","first-page":"786","article-title":"An E1B-19kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency, Molecular therapy : the journal of the American Society of","volume":"9","author":"Liu","year":"2004","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.engmic.2024.100140_bib0240","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(89)90984-7","article-title":"Cellular targets for transformation by the adenovirus E1A proteins","volume":"56","author":"Whyte","year":"1989","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.engmic.2024.100140_bib0241","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/hum.1998.9.9-1323","article-title":"A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy","volume":"9","author":"Freytag","year":"1998","journal-title":"Hum. Gene Ther."},{"issue":"14","key":"10.1016\/j.engmic.2024.100140_bib0242","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clinical Oncology"}],"container-title":["Engineering Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667370324000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667370324000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:36:03Z","timestamp":1778931363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667370324000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":242,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2667370324000031"],"URL":"https:\/\/doi.org\/10.1016\/j.engmic.2024.100140","relation":{},"ISSN":["2667-3703"],"issn-type":[{"value":"2667-3703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of homologous recombination\/recombineering on human adenovirus genome engineering: Not the only but the most competent solution","name":"articletitle","label":"Article Title"},{"value":"Engineering Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.engmic.2024.100140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Shandong University.","name":"copyright","label":"Copyright"}],"article-number":"100140"}}